

**NGHE AN PHARMACEUTICAL MEDICAL MATERIALS  
AND EQUIPMENT JOINT - STOCK COMPANY**

**COMBINED FINANCIAL STATEMENTS**

**For the financial year ended 31 December 2025, audited by**

**NHAN TAM VIET AUDITING COMPANY LIMITED – HANOI BRANCH**

## TABLE OF CONTENTS

<b>Content</b>	<b>Page</b>
<b>Report of the Board of General Directors</b>	<b>2 – 3</b>
<b>Independent Auditor’s Report</b>	<b>4 – 5</b>
<b>Audited Combined Financial Statements</b>	<b>6 – 39</b>
<i>Balance Sheet as at 31 December 2025</i>	<i>6 – 9</i>
<i>Income Statement for 2025</i>	<i>10</i>
<i>Cash Flow Statement for 2025</i>	<i>11 – 12</i>
<i>Notes to the Combined Financial Statements for 2025</i>	<i>13 – 39</i>

## REPORT OF THE BOARD OF GENERAL DIRECTOR

The Board of Directors of Nghe An Pharmaceutical Medical Material and Equipment Joint-Stock Company presents its report together with the combined financial statements for the fiscal year ended December 31, 2025, which have been audited.

### Overview of the Company

Nghe An Pharmaceutical Medical Material and Equipment Joint-Stock Company was established and operates under Enterprise Registration Certificate No. 2900491298, initially issued on January 30, 2002 by the Department of Planning and Investment of Nghe An Province.

During its operation, the Company has had its Enterprise Registration Certificate amended 13 times by the Department of Planning and Investment of Nghe An Province regarding supplementation of registered business lines, changes in charter capital, and changes in the legal representative. The 13th amended Enterprise Registration Certificate was issued by the Department of Planning and Investment of Nghe An Province on October 10, 2024.

*The charter capital as stated in the 13th amended Enterprise Registration Certificate is VND 60,000,000,000*

*The contributed charter capital as at December 31, 2025 is VND 60,000,000,000*

### Head office

Address : No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province.

Tax code : 2 9 0 0 4 9 1 2 9 8

### Financial position and business performance

The combined financial position as at December 31, 2025, and the combined results of operations and combined cash flows for the fiscal year then ended of the Company are presented in the combined financial statements accompanying this report (from page 06 to page 39).

### Board of Directors and Management

The Board of Directors, the General Director and the management of the Company during the year and up to the date of this report comprise:

#### Board of Management

<u>Full name</u>	<u>Position</u>
Mr. Nguyen Van Thang	Chairman of the Board of Directors
Mr. Lang Van Hieu	Member of the Board of Directors
Ms. Phan Thi Thu Hien	Member of the Board of Directors

#### Supervisory Board

<u>Full name</u>	<u>Position</u>
Ms. Dang Thi Huong Lan	Head of the Supervisory Board
Mr. Dao Manh Hung	Member of the Supervisory Board
Mr. Nguyen Viet Hung	Member of the Supervisory Board

#### Board of Directors

<u>Full name</u>	<u>Position</u>	
Mr. Nguyen Cong Que	Director	Dismissed on March 05, 2025
Mr. Tran Cong Vinh	Deputy Director	

#### Chief Accountant

<u>Full name</u>	<u>Position</u>	
Mr. Nguyen Phi Hao	Chief Accountant	Appointed on May 28, 2025
Ms. Nguyen Thi Hien	Person in charge of accounting	Dismissed on May 28, 2025

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**  
**REPORT OF THE BOARD OF MANAGEMENT (CONTINUED)**

**Auditor**

Nhan Tam Viet Auditing Company Limited – Hanoi Branch has audited the Financial Statements for the financial year ended 31 December 2025.

**Confirmation of the General Director**

The General Director of the Company is responsible for the preparation of the Financial Statements which give a true and fair view of the financial position, the results of operations and the cash flows of the Company for the year. In preparing the Financial Statements, the General Director confirms that the following requirements have been complied with:

- Establishing and maintaining internal control that the General Director considers necessary to ensure that the Financial Statements are free from material misstatement, whether due to fraud or error;
- Selecting appropriate accounting policies and applying them consistently;
- Making reasonable and prudent judgments and estimates;
- Stating whether applicable accounting standards have been complied with and disclosing and explaining any material departures in the Financial Statements;
- Preparing and presenting the Financial Statements in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System for Enterprises and relevant legal regulations relating to the preparation and presentation of the Financial Statements;
- Preparing the Financial Statements on a going concern basis unless it is inappropriate to presume that the Company will continue its business operations.

The Board of Management of the Company ensures that accounting books are maintained to reflect the financial position of the Company with reasonable accuracy at any point in time and that the combined financial statements comply with current State regulations. The Board of Management is also responsible for safeguarding the Company's assets and for implementing appropriate measures to prevent and detect fraud and other irregularities. The combined financial position as at December 31, 2025, and the combined results of operations and combined cash flows for the fiscal year then ended are prepared in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System for enterprises, and comply with relevant legal regulations relating to the preparation and presentation of financial statements.

**Other commitments**

The Board of Management commits that the Company complies with the Law on Securities No. 54/2019/QH14 dated November 26, 2019, the amended Law on Securities No. 56/2024/QH15 dated November 29, 2024, and the guiding circulars and decrees on information disclosure in the securities market.

Nghe An, March 27, 2026

On behalf of the Board of Management



**Tran Cong Vinh**

No : 2312.01.01/2025/BCTC-NTVHN

**INDEPENDENT AUDITOR'S REPORT**  
**On the Combined Financial Statements for 2025**To : Shareholders, the Board of Directors, the Board of Management  
Nghe An Pharmaceutical Medical Material and Equipment Joint - Stock Company

We have audited the accompanying combined financial statements of Nghe An Pharmaceutical Medical Material and Equipment Joint-Stock Company, prepared on March 27, 2026 from page 06 to page 39, which comprise the combined balance sheet as at December 31, 2025, the combined statement of income, the combined statement of cash flows for the fiscal year then ended, and the notes to the combined financial statements.

**Responsibility of the General Director**

The Board of Management of Nghe An Pharmaceutical Medical Material and Equipment Joint-Stock Company is responsible for the preparation and fair presentation of the Company's combined financial statements in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System for enterprises, and relevant legal regulations relating to the preparation and presentation of combined financial statements, and for such internal control as the Board of Management determines is necessary to enable the preparation and presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these Combined Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Company's Combined Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Combined Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Combined Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers the Company's internal control relevant to the preparation and fair presentation of the Combined Financial Statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the General Director, as well as evaluating the overall presentation of the Combined Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Trụ Sở Chính:**Tầng 2, tòa nhà Platinum Residences, số 6 Nguyễn Công Hoan,  
Phường Ngọc Khánh, Quận Ba Đình, Thành phố Hà Nội, Việt Nam 4[T] (84-24) 3761 3399  
[W] www/vpaudit.vn[F] (84-24) 3761 5599  
[E] vpa@ntva.vn**Chi nhánh tại Hà Nội:**

Số 12 Phố Mễ Trì Hạ, P. Mễ Trì, Q. Nam Từ Liêm, TP. Hà Nội

**Chi nhánh tại TP. Hồ Chí Minh:**

98 Vũ Tông Phan, P. An Phú, Q. 2, TP. Hồ Chí Minh

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

**Auditor's Opinion**

In our opinion, the combined financial statements referred to above present fairly, in all material respects, the combined financial position of Nghe An Pharmaceutical Medical Material and Equipment Joint-Stock Company as at December 31, 2025, and its combined results of operations and combined cash flows for the fiscal year then ended, in accordance with Vietnamese Accounting Standards, the Vietnamese Accounting System, and relevant legal regulations relating to the preparation and presentation of combined financial statements.

*Ha Noi, March 27, 2026*

**NHAN TAM VIET AUDITING COMPANY LIMITED – HANOI BRANCH**  
**Deputy Director**

**Auditor**



**Pham Van Tuan**

Certificate of Auditor Registration No.:  
4497-2023-124-1

**Nguyen Thi Thuy**

Certificate of Auditor Registration No.:  
6229-2023-124-1

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the fiscal year ending December 31, 2025

**COMBINED BALANCE SHEET**

As of December 31, 2025

Unit: VND

ASSET	Code	Note	<u>Ending Balance</u>	<u>Beginning Balance</u>
<b>A - SHORT-TERM ASSETS</b>	<b>100</b>		<b>67,406,945,328</b>	<b>73,900,423,361</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>	<b>V.1</b>	<b>9,315,999,368</b>	<b>12,177,682,808</b>
1. Cash	111		7,315,999,368	5,177,682,808
2. Cash equivalents	112		2,000,000,000	7,000,000,000
<b>II. Short-term financial investment</b>	<b>120</b>		-	-
1. Trading securities	121		-	-
2. Provision for impairment of trading securities	122		-	-
3. Held to maturity investment	123		-	-
<b>III. Short-term receivables</b>	<b>130</b>		<b>28,269,124,093</b>	<b>36,929,551,948</b>
1. Short-term trade receivables	131	V.2	26,340,896,564	31,597,192,947
2. Short-term vendor advance	132	V.3	1,983,515,957	5,497,726,906
3. Short-term internal receivables	133		-	-
4. Receivable according to construction contract progr	134		-	-
5. Short-term loan receivable	135		-	-
6. Other short-term receivables	136	V.4	1,497,874,436	1,344,380,663
7. Provision for doubtful short-term receivables	137	V.5	(1,553,162,864)	(1,509,748,568)
8. Assets missing pending resolution	139		-	-
<b>IV. Inventory</b>	<b>140</b>		<b>29,031,838,302</b>	<b>24,484,554,411</b>
1. Inventory	141	V.6	29,098,926,143	24,622,253,897
2. Provision for inventory write-down	149		(67,087,841)	(137,699,486)
<b>V. Other short-term assets</b>	<b>150</b>		<b>789,983,565</b>	<b>308,634,194</b>
1. Short-term prepaid expenses	151	V.7a	286,651,706	114,683,213
2. Deductible value added tax	152		293,348,156	178,101,778
3. Taxes and other amounts receivable from the State	153	V.13	209,983,703	15,849,203
4. Government bond repurchase transaction	154		-	-
5. Other short-term assets	155		-	-

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

COMBINED FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2025

Combined Balance Sheet (continued)

ASSET	Code	Note	Ending Balance	Beginning Balance
<b>B - LONG-TERM ASSETS</b>	<b>200</b>		<b>57,484,422,899</b>	<b>51,214,778,925</b>
<b>I. Long-term receivables</b>	<b>210</b>			
1. Long-term receivables from customers	211		-	-
2. Long-term prepayment to seller	212		-	-
3. Working capital in affiliated units	213		-	-
4. Long-term internal receivables	214		-	-
5. Long-term loan receivable	215		-	-
6. Other long-term receivables	216		-	-
7. Provision for doubtful long-term receivables	219		-	-
<b>II. Fixed assets</b>	<b>220</b>		<b>1,626,795,831</b>	<b>2,356,754,980</b>
1. Tangible fixed assets	221	V.8	1,503,232,533	2,186,221,674
<i>Original price</i>	222		49,529,801,168	50,086,017,890
<i>Accumulated depreciation</i>	223		(48,026,568,635)	(47,899,796,216)
2. Financial lease fixed assets	224		-	-
<i>Original price</i>	225		-	-
<i>Accumulated depreciation</i>	226		-	-
3. Intangible fixed assets	227	V.9	123,563,298	170,533,306
<i>Original price</i>	228		587,553,000	587,553,000
<i>Accumulated depreciation</i>	229		(463,989,702)	(417,019,694)
<b>III. Investment real estate</b>	<b>230</b>			
Original price	231		-	-
Accumulated depreciation	232		-	-
<b>IV. Long-term unfinished assets</b>	<b>240</b>	V.10	<b>54,663,128,119</b>	<b>47,344,399,991</b>
1. Long-term unfinished production and business costs	241		-	-
2. Cost of unfinished basic construction	242		54,663,128,119	47,344,399,991
<b>V. Long-term financial investment</b>	<b>250</b>			
1. Investment in subsidiaries	251		-	-
2. Investment in joint ventures and associates	252		-	-
3. Investing in other entities	253		-	-
4. Long-term financial investment reserve	254		-	-
5. Held to maturity investment	255		-	-
<b>VI. Other long-term assets</b>	<b>260</b>		<b>1,194,498,949</b>	<b>1,513,623,954</b>
1. Long-term prepaid expenses	261	V.7b	1,194,498,949	1,513,623,954
2. Deferred income tax assets	262		-	-
3. Long-term replacement equipment, supplies and spa	263		-	-
4. Other long-term assets	268		-	-
<b>TOTAL ASSETS</b>	<b>270</b>		<b>124,891,368,227</b>	<b>125,115,202,286</b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the fiscal year ending December 31, 2025

**Combined Balance Sheet (continued)**

CAPITAL SOURCE	Code	Note	Ending Balance	Beginning Balance
<b>C - LIABILITIES PAYABLE</b>	<b>300</b>		<b>33,502,655,052</b>	<b>36,716,246,717</b>
<b>I. Short-term debt</b>	<b>310</b>		<b>29,684,630,254</b>	<b>32,993,810,519</b>
1. Short-term trade payables	311	V.11	23,299,807,112	28,825,228,011
2. Short-term advance payment buyer	312	V.12	100,891,288	70,543,869
3. Taxes and other payments to the State	313	V.13	1,038,089,376	773,012,243
4. Payable to workers	314		2,383,305,243	1,116,669,912
5. Short-term payable expenses	315	V.14	2,209,374,810	1,413,398,695
6. Short-term internal payables	316		-	-
7. Payable according to construction contract progress	317		-	-
8. Short-term unearned revenue	318	V.15	74,506,061	45,881,798
9. Other short-term payables	319	V.16a	576,830,909	747,292,534
10. Short-term loans and finance leases	320		-	-
11. Provision for short-term payables	321		-	-
12. Bonus and welfare fund	322	V.18	1,825,455	1,783,457
13. Price stabilization fund	323		-	-
14. Government bond repurchase transaction	324		-	-
<b>II. Long-term debt</b>	<b>330</b>		<b>3,818,024,798</b>	<b>3,722,436,198</b>
1. Long-term trade payables	331		-	-
2. Long term prepayment buyer	332		-	-
3. Long-term payable expenses	333		-	-
4. Internal payable on working capital	334		-	-
5. Long-term internal payables	335		-	-
6. Long-term unrealized revenue	336		-	-
7. Other long-term payables	337	V.16b	3,537,024,798	3,441,436,198
8. Long-term loans and financial leases	338	V.17	281,000,000	281,000,000
9. Convertible bonds	339		-	-
10. Preferred stock	340		-	-
11. Deferred income tax payable	341		-	-
12. Long-term payables provision	342		-	-
13. Science and Technology Development Fund	343		-	-

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province


**COMBINED FINANCIAL STATEMENTS**

For the fiscal year ending December 31, 2025

**Combined Balance Sheet (continued)**

CAPITAL SOURCE	Code	Note	Ending Balance	Beginning Balance
<b>D - OWNER'S EQUITY</b>	<b>400</b>		<b>91,388,713,175</b>	<b>88,398,955,569</b>
<b>I. Equity</b>	<b>410</b>	<b>V.19</b>	<b>91,388,713,175</b>	<b>88,398,955,569</b>
1. Owner's equity	411		60,000,000,000	60,000,000,000
- Common shares with voting rights	411a		60,000,000,000	60,000,000,000
- Preferred stock	411b		-	-
2. Capital surplus	412		-	-
3. Bond conversion option	413		-	-
4. Other owners' equity	414		423,999,999	423,999,999
5. Treasury stock	415		-	-
6. Asset revaluation difference	416		-	-
7. Exchange rate difference	417		-	-
8. Development investment fund	418		19,006,550,476	18,420,072,754
9. Enterprise Reorganization Support Fund	419		-	-
10. Other equity funds	420		-	-
11. Undistributed profit after tax	421		11,958,162,700	9,554,882,816
- Undistributed profit after tax accumulated to the en	421a		8,733,814,005	7,208,971,929
- Undistributed profit this period	421b		3,224,348,695	2,345,910,887
12. Source of capital for basic construction investment	422		-	-
<b>II. Other funding sources and funds</b>	<b>430</b>		-	-
1. Funding sources	431		-	-
2. Funds for forming fixed assets	432		-	-
<b>TOTAL CAPITAL</b>	<b>440</b>		<b>124,891,368,227</b>	<b>125,115,202,286</b>

Prepared by



Nguyen Thi Hien

Chief Accountant



Nguyen Phi Hao

Nghe An, March 27, 2025

Deputy Director



Tran Cong Vinh

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

COMBINED FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2025

**COMBINED BUSINESS PERFORMANCE REPORT**

2025

Unit: VND

INDICATORS	Code	Note	This year	Last year
1. Sales and service revenue	01	VI.1	141,509,190,051	172,557,725,154
2. Revenue deductions	02	VI.2	-	422,934,928
3. Net revenue from sales and services	10		141,509,190,051	172,134,790,226
4. Cost of goods sold	11	VI.3	104,584,167,721	130,997,996,402
5. Gross profit from sales and service provision	20		36,925,022,330	41,136,793,824
6. Financial revenue	21	VI.4	91,558,089	360,604,768
7. Financial costs	22	VI.5	253,696,981	163,540,358
Including: interest expense	23		78,246,575	27,184,932
8. Cost of sales	25	VI.6	17,215,882,397	20,543,885,078
9. Business management costs	26	VI.7	15,698,274,041	17,434,351,825
10. Net operating profit	30		3,848,727,000	3,355,621,331
11. Other income	31	VI.8	351,431,863	194,698,500
12. Other costs	32	VI.9	11,272,666	330,177,939
13. Other profits	40		340,159,197	(135,479,439)
14. Total accounting profit before tax	50		4,188,886,197	3,220,141,892
15. Current corporate income tax expense	51	VI.10	964,537,502	874,231,005
16. Deferred corporate income tax expense	52		-	-
17. Profit after corporate income tax	60		<u>3,224,348,695</u>	<u>2,345,910,887</u>
18. Basic earnings per share	70	VI.11	<u>483.65</u>	<u>351.89</u>
19. Diluted earnings per share	71	VI.11	<u>483.65</u>	<u>351.89</u>

Prepared by



Nguyen Thi Hien

Chief Accountant



Nguyen Phi Hao

Nghe An, March 27, 2025



Deputy Director

Tran Cong Vinh

NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

COMBINED FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2025

**COMBINED CASH FLOW STATEMENT**

(By indirect method)

2025

Unit: VND

INDICATORS	Code Note	This year	Last year
<b>I. Cash flow from operating activities</b>			
1. Profit before tax	01	4,188,886,197	3,220,141,892
2. Adjustments for the following items:			
- Depreciation of fixed assets and investment real estate	02	896,378,149	1,452,066,769
- Provisions	03	(27,197,349)	115,298,035
- Exchange rate gains and losses due to revaluation foreign currency monetary items	04	8,533,923	(3,188,700)
- Profit and loss from investment activities	05	(231,601,584)	(214,328,402)
- Interest expense	06	78,246,575	27,184,932
- Other adjustments	07	-	-
3. Profit from operations			
before changes in working capital	08	4,913,245,911	4,597,174,526
- Increase, decrease receivables	09	8,846,702,197	184,598,872
- Increase, decrease inventory	10	(4,476,672,246)	8,875,047,794
- Increase, decrease payables	11	(3,522,322,869)	(2,818,225,693)
- Increase, decrease prepaid expenses	12	147,156,512	(24,887,972)
- Increase, decrease trading securities	13	-	-
- Interest paid	14	-	(27,184,932)
- Corporate income tax paid	15	(741,723,994)	(725,259,296)
- Other income from operating activities	16	-	-
- Other expenses for business activities	17	(234,549,091)	(255,683,712)
<b>Net cash flow from operating activities</b>	<b>20</b>	<b>4,931,836,420</b>	<b>9,805,579,587</b>
<b>II. Cash flow from investing activities</b>			
1. Money spent on purchasing and constructing fixed assets and other long-term assets	21	(8,071,028,126)	(2,605,609,558)
2. Proceeds from liquidation and sale of fixed assets and other long-term assets	22	160,000,000	-
3. Money spent on lending, buying debt instruments other units	23	-	-
4. Proceeds from loan recovery, resale of debt instruments other units	24	-	2,660,000,000
5. Money spent on investment in other entities	25	-	-
6. Proceeds from capital investment in other entities	26	-	-
7. Interest income, dividends and profits	27	118,413,066	184,439,253
<b>Net cash flow from investing activities</b>	<b>30</b>	<b>(7,792,615,060)</b>	<b>238,829,695</b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province


**COMBINED FINANCIAL STATEMENTS**

For the fiscal year ending December 31, 2025

**Combined Cash Flow Statement (continued)**

INDICATORS	Code	Note	This year	Last year
<b>III Cash flow from financing activities</b>				
1. Proceeds from issuing shares, receiving capital contributions owner	31		-	-
2. Money returned to owners, buyback issued company shares	32		-	-
3. Proceeds from borrowing	33		20,000,000,000	-
4. Loan principal repayment	34		(20,000,000,000)	(4,560,000,000)
5. Lease principal repayment	35		-	-
6. Dividends, profits paid to owners	36		(3,135,000)	(5,978,340,000)
<i>Net cash flow from financing activities</i>	<b>40</b>		<u>(3,135,000)</u>	<u>(10,538,340,000)</u>
<b>Net cash flow during the year</b>	<b>50</b>		<b>(2,863,913,640)</b>	<b>(493,930,718)</b>
<b>Cash and cash equivalents at the beginning of the year</b>	<b>60</b>	V.1	<b>12,177,682,808</b>	<b>12,668,424,826</b>
Impact of Foreign Exchange Rate Fluctuations on Currency Translation	61		2,230,200	3,188,700
<b>Cash and cash equivalents at the end of the year</b>	<b>70</b>	V.1	<u><b>9,315,999,368</b></u>	<u><b>12,177,682,808</b></u>

Prepared by



Nguyen Thi Hien

Chief Accountant



Nguyen Phi Hao



Nghe An, March 27, 2025

Deputy Director

Tran Cong Vinh

**COMBINED FINANCIAL STATEMENTS NOTES**  
**For the year 2025**

**I. CHARACTERISTICS OF THE COMPANY'S OPERATIONS**

**1. Overview of the Company**

Nghe An Pharmaceutical Medical Material And Equipment Joint-Stock Company was established and operates under Enterprise Registration Certificate No. 2900491298 issued on January 30, 2002 by the Department of Planning and Investment of Nghe An Province.

During its operation, the Company has amended its Enterprise Registration Certificate 13 times as issued by the Department of Planning and Investment of Nghe An Province regarding the addition of registered business lines, changes in charter capital, and changes in the legal representative. The 13th amended Enterprise Registration Certificate was issued by the Department of Planning and Investment of Nghe An Province on October 10, 2024.

*The charter capital as per the 13th amended Enterprise Registration Certificate is VND 60,000,000,000*

*The contributed charter capital as at December 31, 2025 is VND 60,000,000,000*

**Head office**

Address : No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province.  
 Tax code : 2 9 0 0 4 9 1 2 9 8

2. **Form of ownership of capital** : Joint Stock Company
3. **Business lines** : Manufacture of pharmaceuticals, chemical drugs and medicinal materials.
4. **Business activities** :  
 Manufacture of medicines, functional foods, micronutrient-fortified foods, chemical pharmaceuticals, medicinal materials, pharmaceutical raw materials and excipients, and processing of medicinal materials
5. **Usual operating cycle:** Within 12 months
6. **Company structure**

*Dependent units without separate legal entity, accounted for as dependent units*

<u>Unit name</u>	<u>Address</u>	<u>Principal business activities</u>
GMP-WHO Pharmaceutical Factory	No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An	Trading of medicines and functional foods
Vinh City Pharmaceutical Branch	No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province	Trading of medicines and functional foods
Nghe An Pharmaceutical – Medical Supplies Company Branch in Ha Noi	No. 356 Giai Phong Street, Phuong Liet Ward, Ha Noi City	Trading of medicines and functional foods
Anh Son District Pharmaceutical Branch	Residential Group 02, Anh Son Commune, Nghe An	Trading of medicines and functional foods
Con Cuong District	Block 3, Con Cuong Commune, Nghe	Trading of medicines and

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

<u>Unit name</u>	<u>Address</u>	<u>Principal business activities</u>
Pharmaceutical Branch	An	functional foods
Dien Chau District Pharmaceutical Branch	Block 4, Dien Chau Commune, Nghe An	Trading of medicines and functional foods
Do Luong District Pharmaceutical Branch	Block 3, Do Luong Commune, Nghe An	Trading of medicines and functional foods
Hung Nguyen District Pharmaceutical Branch	Tan Hop Hamlet, Hung Nguyen Commune, Nghe An	Trading of medicines and functional foods
Quy Chau District Pharmaceutical Branch	Block 3, Quy Chau Commune, Nghe An	Trading of medicines and functional foods
Ky Son District Pharmaceutical Branch	Block 3, Muong Xen Commune, Nghe An	Trading of medicines and functional foods
Nam Dan District Pharmaceutical Branch	159 Phan Boi Chau Block, Van An Commune, Nghe An	Trading of medicines and functional foods
Nghia Dan District Pharmaceutical Branch	Tan Tien Block, Thai Hoa Ward, Nghe An	Trading of medicines and functional foods
Que Phong District Pharmaceutical Branch	Nam Son Block, Que Phong Commune, Nghe An	Trading of medicines and functional foods
Quynh Luu District Pharmaceutical Branch	Block 5, Quynh Luu Commune, Nghe An	Trading of medicines and functional foods
Quy Hop District Pharmaceutical Branch	Block 1, Quy Hop Commune, Nghe An	Trading of medicines and functional foods
Tan Ky District Pharmaceutical Branch	Block 3, Tan Ky Commune, Nghe An	Trading of medicines and functional foods
Thanh Chuong District Pharmaceutical Branch	Block 2, Dai Dong Commune, Nghe An	Trading of medicines and functional foods
Tuong Duong District Pharmaceutical Branch	Hoa Bac Block, Tuong Duong Commune, Nghe An	Trading of medicines and functional foods
Yen Thanh District Pharmaceutical Branch	Block 4, Yen Thanh Commune, Nghe An	Trading of medicines and functional foods

7. **Statement on comparability of information in the financial statements:** The figures in the Combined Financial Statements for 2025 are fully consistent with and comparable to those in the Combined Financial Statements for 2024.

8. **Employees**

As at the end of the financial year, the Company had 483 employees (beginning of the year: 517 employees).

**II. FISCAL YEAR, CURRENCY USED IN ACCOUNTING**

1. **Fiscal year**

The fiscal year of the Company begins on 01 January and ends on 31 December annually.

2. **Currency used in accounting**

The currency used in accounting is Vietnam Dong (VND).

### III. ACCOUNTING STANDARDS AND ACCOUNTING REGIME APPLIED

#### 1. Accounting regime applied

The Company applies the Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated 22/12/2014, Circular No. 53/2016/TT-BTC in 2016 amending and supplementing Circular No. 200/2014/TT-BTC, and other circulars guiding the implementation of accounting standards and accounting regimes issued by the Ministry of Finance.

#### 2. Statement of compliance with accounting standards and accounting regime

The Board of Management ensures compliance with the requirements of Vietnamese Accounting Standards, the Vietnamese Accounting Regime for Enterprises issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC amending and supplementing Circular No. 200/2014/TT-BTC, as well as other guiding circulars on the implementation of accounting standards issued by the Ministry of Finance in the preparation of the financial statements.

#### 3. Accounting form applied

The Company applies the General Journal accounting form on computer.

### IV. ACCOUNTING POLICIES APPLIED

#### 1. Basis for preparation of the Financial Statements

The Financial Statements are prepared on the accrual basis of accounting (except for information relating to cash flows).

#### 2. Types of exchange rates applied in accounting and principles for accounting of exchange rate differences

The Company has transactions denominated in foreign currencies: USD.

Exchange rate differences arising during the year and those resulting from the revaluation of foreign currency monetary items at year-end are recognized as income or expenses in the year. Exchange rate differences arising from the revaluation of foreign currency balances at year-end are accounted for in accordance with the guidance of Circular No. 200/2014/TT-BTC dated December 22, 2014 of the Ministry of Finance.

Transactions in foreign currencies are translated at the exchange rates prevailing at the transaction dates. Year-end balances of foreign currency monetary items are translated at the exchange rates prevailing at the end of the financial year.

Exchange rate differences arising during the year from foreign currency transactions of monetary items and those arising from the revaluation of foreign currency monetary items at year-end, after offsetting gains and losses, are recognized in financial income or financial expenses.

The exchange rates used for translating foreign currency transactions are the actual exchange rates at the transaction dates of the commercial banks where the Company conducts transactions. The exchange rates used for revaluing year-end balances of foreign currency monetary items are the buying rates of the commercial banks or the average buying rates of the commercial banks where the Company maintains accounts, as announced at the end of the financial year.

#### 3. Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, bank deposits, cash in transit and short-term investments with an original maturity of no more than 3 months from the date of acquisition, which are readily convertible into known amounts of cash and subject to an insignificant risk of changes in value.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**4. Financial investments**

***Held-to-maturity investments***

An investment is classified as held-to-maturity when the Company has the intention and ability to hold it until maturity. Held-to-maturity investments include term bank deposits (including treasury bills and promissory notes), bonds, redeemable preference shares that the issuer is required to repurchase at a specified date in the future, loans held to maturity for the purpose of earning periodic interest, and other held-to-maturity investments.

Held-to-maturity investments are initially recognized at cost, including purchase price and directly attributable transaction costs. Subsequent to initial recognition, these investments are measured at recoverable amount. Interest income from held-to-maturity investments after the acquisition date is recognized in the Statement of Profit or Loss on an accrual basis. Interest receivable relating to the period prior to acquisition is deducted from the cost of the investment at the acquisition date.

When there is objective evidence that part or all of an investment may not be recoverable and the loss can be reliably measured, such loss is recognized in financial expenses in the year and directly deducted from the carrying amount of the investment.

**5. Receivables**

Receivables are presented at carrying value less allowance for doubtful receivables. The classification of receivables into trade receivables, internal receivables and other receivables is performed based on the following principles:

- Trade receivables represent amounts due of a commercial nature arising from transactions of purchase and sale between the Company and buyers who are independent entities, including receivables from entrusted export sales to other entities.
- Other receivables represent amounts due that are non-commercial in nature and not related to purchase and sale transactions.

Allowance for doubtful receivables is made for each doubtful debt based on the aging of overdue receivables or the estimated level of potential loss, specifically as follows:

- For overdue receivables: the allowance is made based on the period of overdue, specifically as follows:
  - For receivables overdue from 6 months to less than 1 year: allowance is made at a rate of 30%.
  - For receivables overdue from 1 year to less than 2 years: allowance is made at a rate of 50%.
  - For receivables overdue from 2 years to less than 3 years: allowance is made at a rate of 70%.
  - For receivables overdue over 3 years: allowance is made at a rate of 100%.
- For receivables not yet overdue but considered unlikely to be recoverable: the allowance is made based on the estimated level of loss.

Increases or decreases in the allowance for doubtful receivables required to be made at the end of the financial year are recognized in administrative expenses.

**6. Principles of inventory recognition**

Inventories are recognized at the lower of cost and net realizable value.

The cost of inventories is determined as follows:

- Raw materials and goods: comprise purchase costs and other directly attributable costs incurred in bringing inventories to their present location and condition.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

- Finished goods: comprise costs of raw materials, direct labor and directly attributable manufacturing overhead allocated based on normal operating capacity/land use right costs, and other directly attributable and related general costs incurred during the investment and construction of real estate finished products.
- Work in progress: comprise costs of main raw materials and other allocated cost components.

Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

The value of inventories is determined using the weighted average method and accounted for using the perpetual inventory method.

**7. Prepaid expenses**

Prepaid expenses comprise actual costs incurred that relate to the results of production and business activities of multiple accounting periods. The Company's prepaid expenses include the following costs:

*Tools and supplies*

Tools and supplies put into use are allocated to expenses on a straight-line basis over a period not exceeding 3 years.

*Other prepaid expenses*

These are costs serving multiple production and business periods, allocated to production and business expenses over a period not exceeding 3 years.

**8. Principles of recognition and depreciation of fixed assets**

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets comprises all costs incurred by the Company to acquire the assets up to the time the assets are ready for use. Subsequent expenditures are only capitalized as part of the cost of the fixed assets when it is probable that they will result in future economic benefits. Expenditures that do not meet these conditions are recognized as production and business expenses in the period.

When tangible fixed assets are disposed of or liquidated, their cost and accumulated depreciation are derecognized, and any resulting gains or losses are recognized in income or expenses for the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives. The depreciation periods of tangible fixed assets are as follows:

<u>Type of fixed assets</u>	<u>Number of years</u>
Buildings and structures	05 – 20
Machinery and equipment	05 – 10
Means of transportation and transmission equipment	08 – 10
Management equipment and tools	03 – 10

**9. Intangible fixed assets**

Intangible fixed assets are stated at cost less accumulated amortization.

The cost of intangible fixed assets comprises all costs incurred by the Company to acquire the assets up to the time the assets are ready for use. Costs related to intangible fixed assets incurred after initial recognition are recognized as production and business expenses in the period, unless such costs are associated with a specific intangible fixed asset and increase the economic benefits derived from such assets.

When intangible fixed assets are sold or liquidated, their cost and accumulated amortization are derecognized, and any resulting gains or losses from disposal are recognized in income or expenses for the year.

The Company's intangible fixed assets include:

***Land use rights***

Land use rights comprise all actual costs directly related to the land used that have been incurred by the Company, including amounts paid to obtain land use rights, compensation, site clearance, land leveling, registration fees, etc. Land use rights with indefinite term are not amortized.

***Software programs***

Costs related to computer software programs that are not an integral part of the related hardware are capitalized. The cost of computer software comprises all costs incurred by the Company up to the time the software is put into use. Computer software is amortized on a straight-line basis over 03 - 10 years.

**10. Construction in progress**

Construction in progress represents costs directly attributable (including borrowing costs in accordance with the Company's accounting policies) to assets under construction, machinery and equipment under installation for production, leasing and management purposes, as well as costs related to ongoing repairs of fixed assets. These assets are stated at cost and are not depreciated.

**11. Principles of accounting for liabilities and accrued expenses**

Liabilities and accrued expenses are recognized for amounts payable in the future relating to goods and services received. Accrued expenses are recognized based on reasonable estimates of amounts payable.

The classification of payables into trade payables, accrued expenses and other payables is carried out in accordance with the following principles:

- Trade payables represent amounts payable of a commercial nature arising from transactions for the purchase of goods, services and assets where the suppliers are independent entities of the Company, including payables arising from imports through entrusted agents.
- Accrued expenses represent amounts payable for goods and services received from suppliers or provided to customers but not yet paid due to the absence of invoices or incomplete supporting accounting documents, as well as amounts payable to employees for accrued leave salaries and other production and business expenses to be accrued.
- Other payables represent amounts payable that are non-commercial in nature and not related to transactions for the purchase, sale or supply of goods and services.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

---

**12. Principles of recognition of unearned revenue**

Reflects the opening balance and movements of unearned revenue of the Company during the financial year.

The Company's unearned revenue represents revenue received in advance from warehouse leasing.

**13. Principles of recognition of owners' equity**

*Contributed capital of owners*

Contributed capital of owners is recognized based on the actual amounts contributed by shareholders.

*Other capital of owners*

Other capital is formed from retained earnings, revaluation of assets, and the residual value between the fair value of assets received as donations, gifts or grants after deducting related taxes payable (if any).

*Retained earnings*

Represents the results of operations (profit or loss) after corporate income tax and the appropriation of profits or settlement of losses of the enterprise.

*Other funds*

Funds are appropriated and utilized in accordance with the Company's Charter and resolutions approved annually by the General Meeting of Shareholders.

*Dividends*

Dividends are recognized as liabilities when declared.

**14. Principles and methods of revenue recognition**

*a) Revenue from sale of goods and finished products*

Revenue from sale of goods is recognized when all of the following conditions are satisfied:

- The significant risks and rewards of ownership of the products or goods have been transferred to the buyer;
- The Company no longer retains managerial involvement to the degree usually associated with ownership nor effective control over the goods;
- The revenue can be measured reliably;
- The Company has received or will receive economic benefits from the sales transaction;
- The costs related to the sales transaction can be measured reliably.

*b) Revenue from rendering of services*

Revenue from rendering of services is recognized when the outcome of the transaction can be measured reliably. Where services are performed over multiple periods, revenue is recognized in the period based on the stage of completion of the services at the end of the accounting period. The outcome of a service transaction is considered to be reliably measured when all of the following conditions are satisfied:

- The revenue can be measured reliably. Where the contract provides the buyer with the right to return the services under specified conditions, revenue is recognized only when those conditions no longer exist and the buyer no longer has the right to return the services rendered.
- It is probable that the economic benefits associated with the service transaction will flow to the Company.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

---

- The stage of completion of the transaction at the end of the financial year can be measured reliably.
- The costs incurred for the transaction and the costs to complete the service transaction can be measured reliably.

*c) Financial income*

Financial income arising from interest, royalties, dividends, profit distributions and other financial income is recognized when both of the following conditions are satisfied:

- It is probable that the economic benefits associated with the transaction will flow to the Company;
- The revenue can be measured reliably.

**15. Accounting principles for revenue deductions**

Revenue deductions include: Trade discounts, sales allowances and sales returns.

Trade discounts, sales allowances and sales returns arising in the same period as the sale of products, goods and services are deducted from revenue of the period incurred;

- In cases where products, goods or services have been sold in prior periods, but trade discounts, sales allowances or sales returns arise in subsequent periods, the enterprise shall record a reduction in revenue in accordance with the principles:

+ If products, goods or services have been sold in prior periods, but price reductions, trade discounts or sales returns arise in subsequent periods before the issuance date of the Financial Statements, the accountant shall treat these as adjusting events occurring after the balance sheet date and record a reduction in revenue in the Financial Statements of the reporting period (the prior period).

+ In cases where products, goods or services are subject to price reductions, trade discounts or sales returns after the issuance date of the Financial Statements, the enterprise shall record a reduction in revenue in the period in which they arise (the subsequent period).

**16. Borrowing costs**

Borrowing costs include interest expenses and other costs incurred in connection with borrowings.

Borrowing costs are recognized as expenses when incurred. In cases where borrowing costs are directly attributable to the investment in construction or production of assets under construction that require a substantial period of time (over 12 months) to be ready for their intended use or for sale, such borrowing costs shall be capitalized. For specific borrowings used for the construction of fixed assets or investment property, borrowing costs are capitalized even if the construction period is less than 12 months. Income arising from the temporary investment of borrowings shall be deducted from the cost of the related assets.

For general borrowings used partly for the purpose of investment in construction or production of assets under construction, the amount of borrowing costs eligible for capitalization is determined based on the capitalization rate applied to the weighted average accumulated expenditures incurred for such investment in construction or production. The capitalization rate is calculated as the weighted average interest rate of the outstanding borrowings during the year, excluding specific borrowings for the purpose of acquiring a qualifying asset.

**17. Accounting principles for cost of goods sold.**

Cost of goods sold during the year is recognized in accordance with the revenue generated in the period and in compliance with the prudence principle.

For direct material costs exceeding normal levels, labor costs and fixed manufacturing overhead not allocated to the cost of inventory, the accountant shall recognize them immediately in cost of goods

sold (after deducting any compensation, if any), even when the products or goods have not yet been determined as sold.

Provision for inventory devaluation is recognized in cost of goods sold based on the quantity of inventories and the difference between the net realizable value and the cost of inventories when the net realizable value is lower than cost. When determining the quantity of inventories subject to write-down for provision, the accountant shall exclude inventories that have been contracted for sale (with net realizable value not lower than the carrying amount) but not yet delivered to customers, provided there is reliable evidence that the customers will not cancel the contracts.

**18. Accounting principles for selling expenses and general and administrative expenses**

Selling expenses reflect the actual costs incurred in the process of selling products, goods and providing services, including expenses for marketing, product introduction, product advertising, sales commissions, warranty expenses for products and goods (excluding construction activities), storage, packaging, transportation, etc.

General and administrative expenses reflect the general management costs of the enterprise, including salaries of administrative personnel (wages, salaries, allowances, etc.); social insurance, health insurance, trade union fees, unemployment insurance of administrative staff; office supplies, tools and equipment, depreciation of fixed assets used for administrative purposes; land rental, business license tax; provision for doubtful receivables; purchased services (electricity, water, telephone, fax, asset insurance, fire insurance, etc.); other cash expenses (entertainment, customer conferences, etc.).

**19. Principles and methods of recognition of current corporate income tax expense**

*Current corporate income tax expense*

Corporate income tax expense represents current income tax, determined based on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses, as well as adjustments for non-taxable income and loss carryforwards.

The Company is subject to corporate income tax at a tax rate of 20%.

**20. Financial instruments**

**i. Financial assets**

*Classification of Financial Assets*

The Company classifies financial assets into the following categories: financial assets recognized at fair value through profit or loss, held-to-maturity investments, loans and receivables, and available-for-sale financial assets. The classification of these financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

*Financial assets recognized at fair value through profit or loss*

Financial assets are classified as at fair value through profit or loss if they are held for trading or are designated as at fair value through profit or loss upon initial recognition.

Financial assets are classified as held-for-trading securities if:

- Acquired or incurred principally for the purpose of selling in the near term;
- The Company intends to hold them for short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are designated as a financial guarantee contract or an effective hedging instrument).

*Held-to-maturity investments*

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that the Company has the positive intention and ability to hold to maturity.

*Loans and receivables*

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market.

*Available-for-sale financial assets*

Available-for-sale financial assets are non-derivative financial assets that are designated as available for sale or are not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

*Initial carrying amount of financial assets*

Financial assets are recognized on the trade date and derecognized on the sale date. At initial recognition, financial assets are measured at purchase price/issuance cost plus directly attributable transaction costs related to the acquisition or issuance of those financial assets.

**ii. Financial liabilities**

The Company classifies financial liabilities into the following categories: financial liabilities at fair value through profit or loss and financial liabilities measured at amortized cost. The classification of financial liabilities depends on the nature and purpose of the financial liabilities and is determined at the time of initial recognition.

*Financial liabilities at fair value through profit or loss*

Financial liabilities are classified as at fair value through profit or loss if they are held for trading or are designated as at fair value through profit or loss upon initial recognition.

Financial liabilities are classified as held-for-trading securities if:

- Issued or incurred principally for the purpose of repurchasing in the near term;
- The Company intends to hold them for short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are designated as a financial guarantee contract or an effective hedging instrument).

*Financial liabilities measured at amortized cost*

Financial liabilities measured at amortized cost are determined as the initial carrying amount of the financial liabilities minus principal repayments, plus or minus the cumulative amortization using the effective interest method of any difference between the initial carrying amount and the maturity amount, and minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility.

The effective interest method is a method of calculating the amortized cost of a financial liability or a group of financial liabilities and allocating interest income or interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts over the expected life of the financial instrument, or a shorter period when appropriate, to the net carrying amount of the financial liability.

*Initial carrying amount of financial liabilities*

At initial recognition, financial liabilities are measured at issuance price plus directly attributable transaction costs related to the issuance of those financial liabilities.

**iii. Equity instruments**

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**21. Related parties**

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating policy decisions.

Transactions with related parties during the year are presented in Note VII.1.

**V. SUPPLEMENTARY INFORMATION FOR ITEMS PRESENTED IN THE COMBINED BALANCE SHEET**

**1. Cash and cash equivalents**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Cash on hand	396,493,987	699,271,671
Demand deposits with banks	6,919,505,381	4,478,411,137
Cash equivalents (1)	2,000,000,000	7,000,000,000
<b>Total</b>	<b><u>9,315,999,368</u></b>	<b><u>12,177,682,808</u></b>

(1) Represents term deposits under fixed-term deposit contracts at Southeast Asia Commercial Joint Stock Bank – Nghe An Branch with a maturity of 3 months and interest rates ranging from 3.55% to 4% per annum

**2. Short-term trade receivables**

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	Value	Provision	Value	Provision
<i>Receivables from other customers</i>	<i>26,340,896,564</i>	<i>(1,314,255,417)</i>	<i>31,597,192,947</i>	<i>(1,270,841,121)</i>
Oncology Hospital - Nghe An	142,184,791	(58,185,236)	1,859,682,636	(58,185,236)
Vinh City General Hospital	59,164,648	(1,000,491)	1,282,450,128	-
Da Phuc Pharmaceutical Co., Ltd.	7,491,244,681	-	8,146,344,994	-
Truong Tho Nghe An Pharmaceutical and Cosmetic Trading Co., Ltd.	1,253,257,706	(188,782,965)	700,380,212	-
Fintex Financial Investment and Depreciation Joint Stock Company	1,151,473,529	-	161,650,000	(2,882,200)
QM Pharma Pharmaceutical Co., Ltd.	1,002,450,390	-	244,020,225	-
SALA MOON TRADING CO., LTD	783,419,464	-	1,494,634,344	-
Other customers at the office	11,698,936,498	(1,066,286,725)	14,770,857,504	(1,209,773,685)
Other customers at branches	2,758,764,857	-	2,937,172,904	-
<b>Total</b>	<b><u>26,340,896,564</u></b>	<b><u>(1,314,255,417)</u></b>	<b><u>31,597,192,947</u></b>	<b><u>(1,270,841,121)</u></b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**3. Short-term advances to suppliers**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Advances to other suppliers</i>	<i>1,983,515,957</i>	<i>5,497,726,906</i>
SINOBRIGHT PHARMA CO.,LTD	-	1,200,460,800
G.A.T Technology Development and Project Management Joint Stock Company	426,699,000	426,699,000
MES M&E Co., Ltd.	754,532,496	-
Hebei Technology Construction and Trading Co., Ltd.	201,600,006	201,600,006
ZHEJIANG XIANJU PHARMACEUTICAL CO., LTD	-	2,651,480,000
T&B Construction Investment Joint Stock Company	-	48,745,500
Other customers	600,684,455	968,741,600
<b>Total</b>	<b><u>1,983,515,957</u></b>	<b><u>5,497,726,906</u></b>

**4. Other short-term receivables**

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	<u>Value</u>	<u>Provision</u>	<u>Value</u>	<u>Provision</u>
<i>Receivables from other organizations and individuals</i>	<i>1,497,874,436</i>	<i>(238,907,447)</i>	<i>1,344,380,663</i>	<i>(238,907,447)</i>
Advances	325,774,766	-	307,283,939	-
Interest receivable from bank deposits	11,865,753	-	44,131,780	-
Deposits and security deposits	755,572,684	-	672,298,764	-
Receivables from social insurance and trade union fees	10,652,776	-	43,928,500	-
Other short-term receivables	394,008,457	(238,907,447)	276,737,680	(238,907,447)
<b>Total</b>	<b><u>1,497,874,436</u></b>	<b><u>(238,907,447)</u></b>	<b><u>1,344,380,663</u></b>	<b><u>(238,907,447)</u></b>

**NE A. AR. SEU. TICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**5. Bad debts**

	Ending Balance		Beginning Balance	
	Overdue period	Original Cost	Overdue period	Original Cost
<b>Trade receivables</b>		<b>1,585,686,252</b>		<b>1,594,422,757</b>
Huu Nghi Nghe An General Hospital	Over 3 years	83,416,246	Over 3 years	83,416,246
Nghe An Oncology Hospital	Over 3 years	58,185,236	Over 3 years	58,185,236
Quy Hop District Medical Center	Over 3 years	47,790,007	Over 3 years	47,796,007
Tuong Duong District Medical Center	Over 3 years	88,138,036	Over 3 years	88,138,036
Hoang Mai Town Medical Center	Over 3 years	134,943,554	Over 3 years	135,506,054
Hong Tung General Clinic - Bach Khoa Medical Pharmaceutical Company Limited	Over 3 years		Over 3 years	
Tran Viet An	Over 3 years	232,748,788	Over 3 years	232,748,788
Mien Trung Construction and Equipment Joint Stock Company	Over 3 years	85,450,000	Over 3 years	85,450,000
Mien Trung Construction and Equipment Joint Stock Company	Over 3 years	1,200,000	Over 3 years	1,200,000
Mien Trung Construction and Equipment Joint Stock Company	Over 3 years	49,200,000	From 2 years to 3 years	49,200,000
Mien Trung Construction and Equipment Joint Stock Company	Over 3 years	13,200,000	From 1 years to 2 years	13,200,000
Nguyen Thi Viet Hong	Over 3 years	-	From 2 years to 3 years	19,453,000
Nguyen Thi Viet Hong	From 2 years to 3 years		From 1 years to 2 years	26,680,500
Nguyen Thi Viet Hong	From 1 years to 2 years	26,680,500	From 6 months to 1 year	26,680,500
Gia Hung Trading Investment Company Limited	Over 3 years	24,359,940	Over 3 years	70,399,999
Other customers	Over 3 years	70,399,999	Over 3 years	70,399,999
<b>Receivables from other organizations and individuals</b>		<b>669,973,946</b>		<b>520,942,518</b>
<b>Total</b>		<b>238,907,447</b>		<b>238,907,447</b>
		<b>1,824,593,699</b>		<b>1,833,330,204</b>
		<b>(238,907,447)</b>		<b>(238,907,447)</b>
		<b>(1,553,162,864)</b>		<b>(1,509,748,568)</b>

**Notes to the combined financial statements (continued)**

Movement of allowance for doubtful receivables is as follows:

	Short-term receivables and loans	Long-term receivables and loans	Total
Beginning Balance	(1,509,748,568)	-	(1,509,748,568)
Additional provision expense	(225,450,309)	-	(225,450,309)
Reversal of provision	182,036,013	-	182,036,013
<b>Ending Balance</b>	<b>(1,553,162,864)</b>	-	<b>(1,553,162,864)</b>

**6. Inventories**

	Ending Balance		Beginning Balance	
	Original Cost	Provision	Original Cost	Provision
Goods in transit	470,645,747	-	-	-
Raw materials	7,220,211,240	-	6,847,479,554	-
Tools and supplies	315,366,288	-	244,603,807	-
Work in progress	376,531,881	-	-	-
Finished goods	12,570,689,521	(15,782,672)	7,073,945,626	(1,763,546)
Merchandise	8,145,481,466	(51,305,169)	10,456,224,910	(135,935,940)
<b>Total</b>	<b>29,098,926,143</b>	<b>(67,087,841)</b>	<b>24,622,253,897</b>	<b>(137,699,486)</b>

Movement of allowance for inventory write-down is as follows:

	This Year	Previous Year
Ending Balance	(137,699,486)	(257,406,273)
Additional provision expense	(67,087,841)	(137,699,486)
Reversal of provision	137,699,486	257,406,273
<b>Beginning Balance</b>	<b>(67,087,841)</b>	<b>(137,699,486)</b>

**7. Prepaid expenses**  
a. Short-term prepaid expenses

	Ending Balance	Beginning Balance
Tools and supplies issued	144,107,172	23,431,903
Insurance expenses	12,686,997	10,713,146
Other short-term prepaid expenses	129,857,537	80,538,164
<b>Total</b>	<b>286,651,706</b>	<b>114,683,213</b>

**b. Long-term prepaid expenses**

Tools and supplies issued	Ending Balance	Beginning Balance
Other long-term prepaid expenses	445,138,889	761,676,060
<b>Total</b>	<b>749,360,060</b>	<b>751,947,894</b>
	<b>1,194,498,949</b>	<b>1,513,623,954</b>

**8. Increase and decrease in tangible fixed assets**

	Buildings and structures	Machinery and equipment	Means of transport and transmission	Management tools and equipment	Total
<b>Original Cost</b>					
Beginning Balance	26,716,055,782	18,957,120,940	3,413,977,738	998,863,430	50,086,017,890
Acquisitions during the year	-	166,419,000	-	-	166,419,000
Disposals and sales	-	-	(722,635,722)	-	(722,635,722)
<b>Ending Balance</b>	<b>26,716,055,782</b>	<b>19,123,539,940</b>	<b>2,691,342,016</b>	<b>998,863,430</b>	<b>49,529,801,168</b>
<i>Including:</i>					
Fully depreciated but still in use	22,359,704,649	18,403,016,401	2,198,923,834	998,863,430	41,037,514,952
<b>Accumulated depreciation</b>					
Beginning Balance	25,098,206,435	18,547,744,811	3,254,981,540	998,863,430	47,899,796,216
Depreciation during the year	626,874,827	160,981,042	61,552,272	-	849,408,141
Disposals and sales	-	-	(722,635,722)	-	(722,635,722)
<b>Ending Balance</b>	<b>25,725,081,262</b>	<b>18,708,725,853</b>	<b>2,593,898,090</b>	<b>998,863,430</b>	<b>48,026,568,635</b>
<b>Remaining Value</b>					
Beginning Balance	1,617,849,347	409,376,129	158,996,198	-	2,186,221,674
<b>Ending Balance</b>	<b>990,974,520</b>	<b>414,814,087</b>	<b>97,443,926</b>	<b>-</b>	<b>1,503,232,533</b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**9. Increase and decrease in intangible fixed assets**

	<u>Land use rights</u>	<u>Software programs</u>	<u>Total</u>
<b>Original Cost</b>			
Beginning Balance	45,000,000	542,553,000	587,553,000
<b>Ending Balance</b>	<u>45,000,000</u>	<u>542,553,000</u>	<u>587,553,000</u>
<i>Including:</i>			
Fully depreciated but still in use	-	40,953,000	<b>40,953,000</b>
<b>Accumulated depreciation</b>			
Beginning Balance	-	417,019,694	417,019,694
Depreciation during the year	-	46,970,008	46,970,008
<b>Ending Balance</b>	<u>-</u>	<u>463,989,702</u>	<u>463,989,702</u>
<b>Remaining Value</b>			
Beginning Balance	45,000,000	125,533,306	170,533,306
<b>Ending Balance</b>	<u>45,000,000</u>	<u>78,563,298</u>	<u>123,563,298</u>

**10. Construction in progress**

	<u>Beginning Balance</u>	<u>Costs incurred during the year</u>	<u>Transferred to fixed assets during the year</u>	<u>Transfer to prepaid expenses</u>	<u>Ending Balance</u>
<i>Construction in progress</i>	47,344,399,991	7,452,937,343	-	(134,209,215)	54,663,128,119
<i>Pharmaceutical manufacturing plant project at Bac Vinh Industrial Park</i>	46,022,892,352	7,432,937,343	-	-	53,455,829,695
<i>Traditional medicine factory project at 68 Nguyen Sy Sach</i>	1,321,507,639	20,000,000	-	(134,209,215)	1,207,298,424
<b>Total</b>	<u>47,344,399,991</u>	<u>7,452,937,343</u>	<u>-</u>	<u>(134,209,215)</u>	<u>54,663,128,119</u>

**NGHE AN PHARMACEUTICAL MEDICAL MATERICAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**11. Short-term trade payables**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Payables to other suppliers</i>	<b>23,299,807,112</b>	<b>28,825,228,011</b>
Da Phuc Pharmaceutical Company Limited	3,139,070,274	926,674,072
CCSC Construction Consulting Services Joint Stock Company	1,330,552,804	-
Thanh Hoa Branch of DANAPHA Pharmaceutical Joint Stock Company	139,872,000	1,825,905,615
CPC 1 Central Pharmaceutical Joint Stock Company	-	1,121,019,185
VINACARE Pharmaceutical Joint Stock Company	899,261,700	1,186,756,520
Vinh Branch of Codupha Central Pharmaceutical Joint Stock Company	1,363,162,637	2,824,703,890
SLCC Law Limited Liability Company	1,242,000,000	1,188,000,000
SINOBRIGHT PHARMA CO., LTD	1,239,719,000	-
Branch of Agimexpharm Pharmaceutical Joint Stock Company	103,573,758	806,742,215
Thanh Binh Pharmaceutical Cosmetics Trading Company Limited	354,116,500	2,343,261,138
Mediplantex Central Pharmaceutical Joint Stock Company	-	1,855,723,620
Other suppliers at the Head Office	13,456,768,757	14,743,176,756
Other suppliers at branches	31,709,682	3,265,000
<b>Total</b>	<b><u>23,299,807,112</u></b>	<b><u>28,825,228,011</u></b>

**12. Short-term advances from customers**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Advances from other customers</i>	<b>100,891,288</b>	<b>70,543,869</b>
Minh An Pharmaceutical Technology Company Limited	95,225,000	-
SAMBATH SERY VATTANAC Company Limited	-	42,805,000
Other customers at the Head Office	5,666,288	3,083,002
Other customers	-	24,655,867
<b>Total</b>	<b><u>100,891,288</u></b>	<b><u>70,543,869</u></b>

**13. Taxes and other payables to the State**

	Beginning Balance		Arising during the year		Ending Balance	
	Payable	Receivable	Amount payable	Amount paid	Payable	Receivable
VAT on domestic sales	-	15,776,649	1,128,762,905	(1,322,897,405)	-	209,911,149
VAT on imports	-	-	1,181,278,830	(1,181,278,830)	-	-
Corporate income tax	741,723,994	-	964,537,502	(741,723,994)	964,537,502	-
Personal income tax	31,288,249	-	300,516,435	(266,738,626)	65,066,058	-
Land rental	-	-	1,354,175,473	(1,345,689,657)	8,485,816	-
Other taxes	-	72,554	25,914,874	(25,914,874)	-	72,554
<b>Total</b>	<b>773,012,243</b>	<b>15,849,203</b>	<b>4,955,186,019</b>	<b>(4,884,243,386)</b>	<b>1,038,089,376</b>	<b>209,983,703</b>

The Company's tax finalization is subject to inspection by the tax authorities. Due to the application of tax laws and regulations to various types of transactions which may be interpreted in different ways, the tax amounts presented in the Financial Statements may be subject to change upon decision of the tax authorities.

**Value-added tax**

The Company applies the credit method for value-added tax with tax rates varying by business sector, specifically:  
 VAT rate applicable to pharmaceutical products 5%  
 VAT rate applicable to domestic consumption goods 8%, 10%

**Corporate income tax**

Details of corporate income tax payable during the year are presented in Note VI.10

**Other taxes**

The Company declares and pays in accordance with regulations.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**14. Short-term accrued expenses**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Payables to other organizations and individuals</i>	2,209,374,810	1,413,398,695
Employee salary expenses	687,475,070	570,393,557
Transportation costs supporting sales	148,528,024	59,584,278
Other short-term accrued expenses	1,373,371,716	783,420,860
<b>Total</b>	<u><u>2,209,374,810</u></u>	<u><u>1,413,398,695</u></u>

**15. Short-term unearned revenue**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Unearned revenue related to other organizations and individuals</i>	74,506,061	45,881,798
Advance receipts from leasing fixed assets and investment property	74,506,061	45,881,798
<b>Total</b>	<u><u>74,506,061</u></u>	<u><u>45,881,798</u></u>

**16. Other payables**

**a. Other short-term payables**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Payables to other entities and individuals</i>	576,830,909	747,292,534
Surplus assets pending resolution	-	4,549,153
Trade union funds	168,717,076	47,338,364
Dividends and profits payable	54,870,100	58,005,100
Interest payable	78,246,575	-
Other short-term payables	274,997,158	637,399,917
<b>Total</b>	<u><u>576,830,909</u></u>	<u><u>747,292,534</u></u>

**b. Other long-term payables**

	<u>Ending Balance</u>	<u>Beginning Balance</u>
<i>Payables to other organizations and individuals</i>	3,537,024,798	3,441,436,198
Deposits received	3,537,024,798	3,441,436,198
<b>Total</b>	<u><u>3,537,024,798</u></u>	<u><u>3,441,436,198</u></u>

**17. Long-term borrowings and finance lease liabilities**

	<u>Ending Balance</u>		<u>Beginning Balance</u>	
	Value	Debt repayment capacity	Value	Debt repayment capacity
<i>Borrowings from state funds for reserve of medicines for natural disaster prevention (*)</i>	281,000,000	281,000,000	281,000,000	281,000,000
<i>Borrowings at Head Office</i>	100,000,000	100,000,000	100,000,000	100,000,000
<i>Borrowings at Con Cuong District Pharmaceutical Branch</i>	85,000,000	85,000,000	85,000,000	85,000,000
<i>Borrowings at Quy Chau District Pharmaceutical Branch</i>	96,000,000	96,000,000	96,000,000	96,000,000
<b>Total</b>	<u><u>281,000,000</u></u>	<u><u>281,000,000</u></u>	<u><u>281,000,000</u></u>	<u><u>281,000,000</u></u>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

(\*) This represents borrowings from the mountainous reserve fund and the project for reserve of medicines for natural disaster prevention.

Details of movements in long-term borrowings and finance lease liabilities are as follows:

	<u>Beginning Balance</u>	<u>Borrowings incurred during the year</u>	<u>Repayments of borrowings during the year</u>	<u>Ending Balance</u>
Long-term borrowings from other entities	281,000,000	-	-	281,000,000
<b>Total</b>	<b>281,000,000</b>	<b>-</b>	<b>-</b>	<b>281,000,000</b>

**18. Bonus and welfare fund**

	<u>Beginning Balance</u>	<u>Increase from appropriation of profit</u>	<u>Expenditures during the year</u>	<u>Ending Balance</u>
Bonus fund	625,165	-	-	625,165
Welfare fund	1,158,292	234,591,089	(234,549,091)	1,200,290
<b>Total</b>	<b>1,783,457</b>	<b>234,591,089</b>	<b>(234,549,091)</b>	<b>1,825,455</b>

19. Equity

a) Statement of changes in equity

	Owner's investment capital	Other capital of owners	Development investment fund	Retained earnings	Total
Beginning balance of previous year	60,000,000,000	423,999,999	17,815,430,103	14,055,471,641	92,294,901,743
Profit for the previous year	-	-	-	2,345,910,887	2,345,910,887
Appropriation to funds	-	-	604,642,651	(846,499,712)	(241,857,061)
Dividends and profit distribution	-	-	-	(6,000,000,000)	(6,000,000,000)
<b>Ending balance of previous year</b>	<b>60,000,000,000</b>	<b>423,999,999</b>	<b>18,420,072,754</b>	<b>9,554,882,816</b>	<b>88,398,955,569</b>
Beginning balance of current year	60,000,000,000	423,999,999	18,420,072,754	9,554,882,816	88,398,955,569
Profit for the current year	-	-	-	3,224,348,695	3,224,348,695
Appropriation to funds (*)	-	-	586,477,722	(821,068,811)	(234,591,089)
<b>Ending balance of current year</b>	<b>60,000,000,000</b>	<b>423,999,999</b>	<b>19,006,550,476</b>	<b>11,958,162,700</b>	<b>91,388,713,175</b>

(\*) Pursuant to the Resolution of the Annual General Meeting of Shareholders in 2025 dated 29/05/2025 approving the appropriation to funds and dividend payment for 2024, details are as follows:

- Appropriation to bonus and welfare fund (10% of profit after tax): 234,591,089 VND
- Appropriation to development investment fund (25% of profit after tax): 586,477,722 VND

b) Details of owner's investment capital

	Ending Balance	Rate	Beginning Balance	Rate
Phuc Khang Financial Investment and Trading Joint Stock Company	11,857,050,000	19.76%	11,857,050,000	19.76%
Hong Ngan Trading and Manufacturing Company Limited	13,069,550,000	21.78%	13,069,550,000	21.78%
Thang Long Wine Trading and Services Joint Stock Company	14,000,000,000	23.33%	14,000,000,000	23.33%
Thung Lung Vua Company Limited	14,971,900,000	24.95%	14,971,900,000	24.95%
Other shareholders	6,101,500,000	10.17%	6,101,500,000	10.17%
<b>Total</b>	<b>60,000,000,000</b>	<b>100.00%</b>	<b>60,000,000,000</b>	<b>100.00%</b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

*c) Shares*

	<u>Ending Balance</u>	<u>Beginning Balance</u>
Number of shares authorized for issuance	6,000,000	6,000,000
Number of shares issued/sold to the public	6,000,000	6,000,000
- Common shares	6,000,000	6,000,000
- Preferred shares	-	-
Number of treasury shares acquired	-	-
- Common shares	-	-
- Preferred shares	-	-
Number of shares outstanding	6,000,000	6,000,000
- Common shares	6,000,000	6,000,000
- Preferred shares	-	-

Par value of shares outstanding: 10,000 VND.

**20. Off-balance sheet items**

*Foreign currencies*

	<u>Ending Balance</u>	<u>Beginning Balance</u>
US Dollar (USD)	2,700	2,700

**VI. SUPPLEMENTARY INFORMATION FOR ITEMS PRESENTED IN THE COMBINED STATEMENT OF PROFIT OR LOSS**

**1. Revenue from sale of goods and provision of services**

	<u>This Year</u>	<u>Previous Year</u>
Revenue from sale of finished goods and merchandise	137,068,821,063	169,317,308,224
Revenue from provision of services	4,440,368,988	3,240,416,930
<b>Total</b>	<b><u>141,509,190,051</u></b>	<b><u>172,557,725,154</u></b>

**2. Revenue Deduction**

	<u>This Year</u>	<u>Previous Year</u>
Sales returns	-	422,934,928
<b>Total</b>	<b><u>-</u></b>	<b><u>422,934,928</u></b>

**3. Cost of goods sold**

	<u>This Year</u>	<u>Previous Year</u>
Cost of finished goods and merchandise sold	99,858,131,397	124,565,529,600
Unallocated manufacturing overhead costs	4,796,647,969	6,312,760,015
Provision/(Reversal of provision) for inventory obsolescence	(70,611,645)	119,706,787
<b>Total</b>	<b><u>104,584,167,721</u></b>	<b><u>130,997,996,402</u></b>

**4. Financial income**

	<u>This Year</u>	<u>Previous Year</u>
Interest income from term deposits	86,147,039	214,328,402
Foreign exchange gain from revaluation of monetary items denominated in foreign currencies	-	3,188,700
Interest income from deferred payment sales, cash discounts	5,411,050	143,087,666
<b>Total</b>	<b><u>91,558,089</u></b>	<b><u>360,604,768</u></b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**5. Financial expenses**

	<u>This Year</u>	<u>Previous Year</u>
Interest expenses	78,246,575	27,184,932
Interest payable on deposits of Mau Dich Vien	-	31,645,882
Foreign exchange losses incurred	166,862,926	101,209,864
Foreign exchange losses from revaluation of monetary items denominated in foreign currencies	8,533,923	-
Other financial expenses	53,557	3,499,680
<b>Total</b>	<b><u>253,696,981</u></b>	<b><u>163,540,358</u></b>

**6. Selling expenses**

	<u>This Year</u>	<u>Previous Year</u>
Staff costs	14,432,392,016	16,476,452,807
Materials and packaging costs	49,639,492	8,490,816
Tools and supplies expenses	-	60,486,840
Depreciation of fixed assets	194,111,459	164,315,808
Purchased services expenses	713,499,035	1,344,442,940
Other expenses	1,826,240,395	2,489,695,867
<b>Total</b>	<b><u>17,215,882,397</u></b>	<b><u>20,543,885,078</u></b>

**7. General and administrative expenses**

	<u>This Year</u>	<u>Previous Year</u>
Staff costs	9,068,673,300	9,381,027,671
Administrative materials expenses	-	56,510,371
Office supplies expenses	338,880,440	444,882,399
Depreciation of fixed assets	270,142,738	378,970,679
Taxes, fees and charges	792,248,528	1,910,247,149
Provision/(Reversal of provision) for doubtful receivables	43,414,296	235,004,822
Purchased services expenses	3,503,648,656	3,451,186,245
Other expenses	1,681,266,083	1,576,522,489
<b>Total</b>	<b><u>15,698,274,041</u></b>	<b><u>17,434,351,825</u></b>

**8. Other income**

	<u>This Year</u>	<u>Previous Year</u>
Gain on disposal and sale of fixed assets	145,454,545	-
Discounts received	40,198,773	68,006,049
Other income	165,778,545	126,692,451
<b>Total</b>	<b><u>351,431,863</u></b>	<b><u>194,698,500</u></b>

**9. Other expenses**

	<u>This Year</u>	<u>Previous Year</u>
Penalties and additional tax payments	1,035,739	318,641,541
Other expenses	10,236,927	11,536,398
<b>Total</b>	<b><u>11,272,666</u></b>	<b><u>330,177,939</u></b>

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

**10. Current corporate income tax expense**

Corporate income tax payable for the year is estimated as follows:

	<u>This Year</u>	<u>Previous Year</u>
Total accounting profit before tax	4,188,886,197	3,220,141,892
Adjustments to increase or decrease accounting profit to determine taxable income for corporate income tax purposes:		
- Adjustments increasing accounting profit	633,801,311	488,478,077
<i>Remuneration of non-executive Board of Directors members</i>	636,031,511	491,666,777
<i>Penalties, fines and tax late payment charges</i>	185,483,333	168,000,000
<i>Other non-deductible expenses</i>	1,035,739	318,641,541
- Adjustments decreasing accounting profit	(2,230,200)	(3,188,700)
<i>Foreign exchange gains from revaluation of items denominated in foreign currencies</i>	(2,230,200)	(3,188,700)
<b>Taxable income</b>	<b>4,822,687,508</b>	<b>3,708,619,969</b>
<b>Assessable income</b>	<b>4,822,687,508</b>	<b>3,708,619,969</b>
Corporate income tax rate	20%	20%
<i>Corporate income tax payable</i>	964,537,502	741,723,994
<i>Adjustment of corporate income tax payable for prior years</i>	-	132,507,011
<b>Total corporate income tax payable outstanding</b>	<b>964,537,502</b>	<b>874,231,005</b>

**11. Basic/diluted earnings per share**

	<u>This Year</u>	<u>Previous Year</u>
Accounting profit after corporate income tax	3,224,348,695	2,345,910,887
Adjustments for increases and decreases in accounting profit to determine profit attributable to ordinary shareholders:		
- Appropriation to bonus and welfare funds (*)	(322,434,870)	(234,591,089)
Profit used to calculate basic/diluted earnings per share	(322,434,870)	(234,591,089)
Weighted average number of ordinary shares outstanding during the year	2,901,913,826	2,111,319,798
<b>Basic/diluted earnings per share</b>	<b>6,000,000</b>	<b>6,000,000</b>
	<b>483,65</b>	<b>351,89</b>

(\*) Provisionally calculated at 10% of profit after tax in accordance with the Resolution of the Annual General Meeting of Shareholders 2025 dated 29/05/2025.

Weighted average number of ordinary shares outstanding during the year is calculated as follows:

	<u>This Year</u>	<u>Previous Year</u>
Ordinary shares outstanding at the beginning of the year	6,000,000	6,000,000
<b>Weighted average number of ordinary shares outstanding during the year</b>	<b>6,000,000</b>	<b>6,000,000</b>

**12. Cost of production and business activities by element**

	<u>This Year</u>	<u>Previous Year</u>
Cost of raw materials	52,527,863,700	71,835,185,236
Labor costs	31,176,406,122	32,942,967,713
Depreciation of fixed assets	896,378,149	1,452,066,769
Provision/(Reversal of provisions)	(27,197,349)	115,298,035
Purchased services expenses	7,559,023,244	6,244,481,963
Other expenses	4,143,299,911	6,353,092,612
<b>Total</b>	<b>96,275,773,777</b>	<b>118,943,092,328</b>

## VII. OTHER INFORMATION

### 1. Transactions with related parties

#### *a. Transactions with key management personnel and related individuals*

Key management personnel include members of the Board of Directors and members of the Executive Management (Board of Management, Chief Accountant). Related individuals to key management personnel are close family members of the key management personnel.

Income of key management personnel during the year is as follows:

	<u>Position</u>	<u>This Year</u>	<u>Previous Year</u>
Mr. Lang Van Hieu	Member of the Board of Directors	488,471,460	531,206,400
Mr. Nguyen Cong Que	Director (dismissed)	113,532,802	660,440,000
Mr. Tran Cong Vinh	Deputy Director	654,943,719	525,921,800
Mr. Nguyen Phi Hao	Chief Accountant	290,880,027	-
Ms. Le Thi Thuy Hong	Chief Accountant	-	77,582,360

### 2. Credit risk

Credit risk is the risk that a party to a contract will be unable to fulfill its obligations, resulting in financial loss to the Company.

The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities (bank deposits, loans and other financial instruments).

#### *Trade receivables*

The Company mitigates credit risk by transacting only with entities that have good financial capacity, requiring letters of credit for first-time counterparties or those without sufficient financial information, and having receivables accounting staff regularly monitor outstanding receivables to ensure timely collection. Based on this and the fact that the Company's receivables relate to a wide range of customers, credit risk is not concentrated on any single customer.

#### *Bank deposits*

The majority of the Company's bank deposits are held at reputable large banks in Vietnam. The Company considers the concentration of credit risk related to bank deposits to be low.

### 3. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting its financial obligations due to a shortage of funds.

The Board of Management has ultimate responsibility for managing liquidity risk. The Company's liquidity risk primarily arises from mismatches in the maturity timing of financial assets and financial liabilities.

The Company manages liquidity risk by maintaining an appropriate level of cash and cash equivalents and borrowings at levels deemed sufficient by the Board of Management to meet the Company's operating needs, thereby minimizing the impact of cash flow fluctuations.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

The maturity of financial liabilities is based on contractual undiscounted cash flows as follows:

	Over 1 year to 5			Total
	Within 1 year	years	Over 5 years	
<b>Beginning Balance</b>				
Borrowings	-	-	281,000,000	281,000,000
Trade payables	23,299,807,112	-	-	23,299,807,112
Other payables	5,244,017,023	3,537,024,798	-	8,781,041,821
<b>Total</b>	<b>28,543,824,135</b>	<b>3,537,024,798</b>	<b>281,000,000</b>	<b>32,361,848,933</b>
<b>Ending Balance</b>				
Borrowings	-	281,000,000	-	281,000,000
Trade payables	28,825,228,011	-	-	28,825,228,011
Other payables	3,323,242,939	3,441,436,198	-	6,764,679,137
<b>Total</b>	<b>32,148,470,950</b>	<b>3,722,436,198</b>	-	<b>35,870,907,148</b>

The Company considers the concentration of risk related to debt repayment to be low. The Company is able to settle its due liabilities from cash flows generated from operating activities and proceeds from maturing financial assets.

**4. Fair value of financial assets and liabilities**

	Book Value		Fair Value	
	Beginning Balance	Ending Balance	Beginning Balance	Ending Balance
<b>Financial assets</b>				
Cash and cash equivalents	9,315,999,368	12,177,682,808	9,315,999,368	12,177,682,808
Trade receivables	25,026,641,147	30,326,351,826	25,026,641,147	30,326,351,826
Other receivables	1,258,966,989	1,105,473,216	1,258,966,989	1,105,473,216
<b>Total</b>	<b>35,601,607,504</b>	<b>43,609,507,850</b>	<b>35,601,607,504</b>	<b>43,609,507,850</b>
<b>Financial liabilities</b>				
Borrowings and debt	281,000,000	281,000,000	281,000,000	281,000,000
Trade payables	23,299,807,112	28,825,228,011	23,299,807,112	28,825,228,011
Other payables	8,781,041,821	6,764,679,137	8,781,041,821	6,764,679,137
<b>Total</b>	<b>32,361,848,933</b>	<b>35,870,907,148</b>	<b>32,361,848,933</b>	<b>35,870,907,148</b>

The fair value of financial assets and financial liabilities is determined as the amount at which a financial instrument could be exchanged in a current transaction between knowledgeable, willing parties.

The Company uses the following methods and assumptions to estimate fair value:

- The fair value of cash and cash equivalents, trade receivables, loans, other receivables, borrowings, trade payables and other short-term payables approximates their carrying amount (net of allowance for doubtful debts) due to their short-term nature.
- The fair value of long-term loans, trade receivables, other receivables, borrowings, trade payables and other payables, and unlisted held-to-maturity investments for which no market prices are available or quoted by three securities companies, is estimated by discounting future cash flows using interest rates applicable to debts with similar characteristics and remaining maturities.

**NGHE AN PHARMACEUTICAL MEDICAL MATERIAL AND EQUIPMENT JOINT-STOCK COMPANY**

Address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province

**COMBINED FINANCIAL STATEMENTS**

For the financial year ended 31 December 2025

**Notes to the combined financial statements (continued)**

5. **Events after the end of the financial year**  
No events have occurred after the end of the financial year that require adjustment or disclosure in the combined financial statements.
6. **Comparative figures**  
The comparative figures are those of the combined financial statements for the financial year ended 31 December 2024, which were audited by Nhan Tam Viet Auditing Company Limited.

Prepared by



Nguyen Thi Hien

Chief Accountant



Nguyen Phi Hao

Prepared on 27 March 2025

Deputy Director



Tran Cong Vinh

